Company: CNTB
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001835268-25-000014
Chunk: 33

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-03-31
Form: 10-K
Item: Item 12
Chunk 33
---
 CategoryNumber ofSecurities to beIssued uponExercise ofOutstandingOptions (a)Weighted-AverageExercise Price ofOutstandingOptions ($)(1)Number ofSecuritiesRemainingAvailable forFuture IssuanceUnder Equity-BasedCompensationPlans (ExcludingSecuritiesReflected inColumn (a))Equity compensation plans approved by security holders:Stock option and award plans9,832,019(2)$3.45 4,374,174(3)ESPP— $— 1,020,251(3)Equity compensation plans not approved by security holders(4)4,431,223 $1.77 68,777 14,263,242$2.93 5,463,202

(1) Represents the weighted-average exercise price of outstanding options. 

(2) Includes 8,342,574 ordinary shares that were subject to outstanding option awards as of December 31, 2024 under the 2021 Plan and 1,489,445 ordinary shares that were subject to outstanding option awards as of December 31, 2024 under the 2019 Plan.

(3) These amounts do not include any additional shares that may become available for future issuance under the 2021 Plan pursuant to the automatic increase to the share reserve on January 1 of each of our calendar years beginning 2025 and continuing through 2031 by the number of shares equal to the lesser of (i) 5% of the total outstanding ordinary shares as of the immediately preceding December 31, and (ii) such smaller number of shares as is determined by our Board. Additionally, this amount does not include any additional shares that may become available for future issuance under the Company’s ESPP pursuant to the automatic increase to the share reserve on January 1 of each of our calendar years beginning 2025 and continuing through 2031 by the number of shares equal to the lesser of (i) 1% of the total outstanding ordinary shares as of the immediately preceding December 31, and (ii) such smaller number of shares as determined by the Board. 

(4) Consists of the Inducement Plan. The terms of the Inducement Plan are substantially similar to the terms of the 2021 Plan with the exception that incentive stock options may not be issued under the Inducement Plan and awards under the Inducement Plan may only be issued to eligible recipients under the applicable Nasdaq rules. The Inducement Plan was adopted by the